Histone Methyltransferase Inhibitors

EZH1

EZH2

DOT1L

SMYD2

SMYD3

SUV39H2/KMT1B

EHMT2/G9a/KMT1C

EHMT1/GLP/KMT1D

SETDB1/KMT2G

SETD2/KMT3A

NSD2/MMSET/WHSC1

SETD7/KMT7

SETD8/KMT5A

PRMT1

PRMT3

PRMT4

PRMT5

PRMT6

PRMT7

PRMT8

Histone Methyltransferase Degraders & Inhibitors

Product Name	EZH1	EZH2	DOT1L	SMYD2	SMYD3	SUV39H2/KMT1B	EHMT2/G9a/KMT1C	EHMT1/GLP/KMT1D	SETDB1/KMT2G	SETD2/KMT3A	NSD2/MMSET/WHSC1	SETD7/KMT7	SETD8/KMT5A	PRMT1	PRMT3	PRMT4	PRMT5	PRMT6	PRMT7	PRMT8	Purity
GSK126		EZH2, IC₅₀: 9.9 nM																			99.98%
Pinometostat			DOT1L																		99.99%
Tazemetostat		EZH2																			99.93%
GSK3326595																	PRMT5				99.97%
3-Deazaneplanocin A hydrochloride		EZH2																			99.98%
GSK343		EZH2																			99.88%
BIX-01294							EHMT2/G9a/KMT1C	EHMT1/GLP/KMT1D													98.75%
MS023														PRMT1	PRMT3			PRMT6		PRMT8	99.73%
UNC1999	EZH1	EZH2																			99.83%
Onametostat																	PRMT5				99.79%
MRTX-1719																	PRMT5				99.40%
UNC0642							EHMT2/G9a/KMT1C	EHMT1/GLP/KMT1D													99.92%
SGC0946			DOT1L, IC₅₀: .3 nM																		99.68%
UNC0379													SETD8/KMT5A								99.90%
UNC0224							G9a, IC₅₀: 15 nM G9a, Ki: 2.6 nM G9a, Kd: 23 nM	EHMT1/GLP/KMT1D, IC₅₀: 20-58 nM													99.31%
MS177		EZH2																			98.00%
A-366							EHMT2/G9a/KMT1C	EHMT1/GLP/KMT1D													98.01%
UNC0638							EHMT2/G9a/KMT1C	EHMT1/GLP/KMT1D													99.71%
TP-064																PRMT4, IC₅₀: <10 nM		PRMT6, IC₅₀: 1300 μM			98.35%
SETDB1-TTD-IN-1									SETDB1/KMT2G												99.61%
CM-272							G9a, IC₅₀: 8 nM	EHMT1/GLP/KMT1D, IC₅₀: 2 nM													99.27%
AMI-1														PRMT1							≥98.0%
SGC707															PRMT3, IC₅₀: 31 nM						98.08%
EZM0414										SETD2/KMT3A											99.45%
LLY-283																	PRMT5				99.22%
MS1943		EZH2, IC₅₀: 120 nM																			98.02%
Valemetostat tosylate	EZH1																				98.14%
OTS186935 hydrochloride						SUV39H2/KMT1B															99.22%
EPZ020411 hydrochloride														PRMT1, IC₅₀: 0.119 μM				PRMT6, IC₅₀: 0.01 μM		PRMT8, IC₅₀: 0.223 μM	98.15%
Valemetostat	EZH1																				99.65%
PFI-2 hydrochloride												SETD7/KMT7									99.52%
SGC3027																			PRMT7		98.29%
AZ505				SMYD2																	99.99%
EPZ-719										SETD2/KMT3A											99.85%
LLY-507				SMYD2, IC₅₀: <15 nM																	98.28%
TNG908																	PRMT5				98.89%
EPZ011989		EZH2																			98.79%
UNC 0631							G9a, IC₅₀: 4 nM														98.35%
EPZ031686					SMYD3, IC₅₀: 3 nM																99.71%
UNC0321							G9a, Ki: 63 pM G9a, IC₅₀: 6-9 nM	EHMT1/GLP/KMT1D, IC₅₀: 15-23 nM													99.80%
PROTAC EZH2 Degrader-1		EZH2, IC₅₀: 2.7 nM																			98.55%
SGC2085																PRMT4					99.45%
GSK503		EZH2																			99.52%
GSK2807 Trifluoroacetate					SMYD3, Ki: 14 nM SMYD3, IC₅₀: 130 nM																99.36%
UNC0646							G9a, IC₅₀: 6 nM	GLP, IC₅₀: <15 nM													99.82%
MRTX9768																	PRMT5				99.60%
JQEZ5		EZH2																			98.08%
EPZ020411														PRMT1, IC₅₀: 0.119 μM				PRMT6, IC₅₀: 0.01 μM		PRMT8, IC₅₀: 0.223 μM	98.06%
MS023 dihydrochloride														PRMT1	PRMT3			PRMT6		PRMT8	99.78%
BVT948													SETD8/KMT5A								≥99.0%
EPZ005687		EZH2, Ki: 24 nM																			99.79%
Furamidine dihydrochloride														PRMT1							≥99.0%
EI1		EZH2 Y641F mutant type, IC₅₀: 13 nM EZH2 WT, EC₅₀: 15 nM																			99.78%
Gambogenic acid		EZH2																			99.94%
PF-06726304		EZH2 WT, Ki: 0.7 nM EZH2 Y641N, Ki: 3.0 nM																			98.37%
DS-437																	PRMT5		PRMT7		98.00%
BAY-6035					SMYD3, IC₅₀: 88 nM																99.82%
EPZ004777 hydrochloride			DOT1L																		99.46%
MS049																PRMT4, : 34 nM		PRMT6, : 43 nM		PRMT8, : 1600 nM	≥98.0%
MS117																		PRMT6			≥98.0%
Tazemetostat de(methylene morpholine)-O-C3-O-C-COOH		EZH2																			98.24%
DCLX069														PRMT1, IC₅₀: 17.9 μM							98.38%
PRMT5-IN-25																	PRMT5, Ki: 0.06 nM				99.94%
BRD0639																	PRMT5				99.17%
RK-701							G9a, IC₅₀: 23-27 nM														98.04%
BRD9539							G9a, IC₅₀: 6.3 μM														99.74%
GNA002		EZH2, IC₅₀: 1.1 μM																			98.02%
EM127					SMYD3																98.37%
PF-06939999																	PRMT5				99.69%
CMP-5																	PRMT5				99.02%
EHMT2-IN-2							EHMT2 PEP, IC₅₀: <100 nM EHMT2 ICW, IC₅₀: <100 nM	EHMTI PEP, IC₅₀: <100 nM													≥99.0%
EZH2-IN-2		EZH2, IC₅₀: 64 nM																			99.40%
HLCL-61 hydrochloride																	PRMT5				99.95%
Dot1L-IN-5			DOT1L, IC₅₀: 0.17 nM																		98.57%
SETDB1-TTD-IN-1 TFA									SETDB1/KMT2G												98.79%
UNC2399		EZH2, IC₅₀: 17 nM																			99.62%
OTS193320						SUV39H2/KMT1B															98.64%
AZ506				SMYD2, IC₅₀: 17 nM																	99.74%
EHMT2-IN-1							EHMT2 PEP, IC₅₀: <100 nM EHMT2 ICW, IC₅₀: <100 nM	EHMTI PEP, IC₅₀: <100 nM													99.85%
SMYD3-IN-1					SMYD3, IC₅₀: 11.7 nM																98.01%
MS8511							G9a, IC₅₀: 100 nM G9a, Kd: 44 nM	GLP, IC₅₀: 140 nM GLP, Kd: 46 nM
NSC745885		EZH2																			≥98.0%
MRTX-1719 hydrochloride																	PRMT5				99.22%
Dot1L-IN-4			DOT1L, IC₅₀: 0.11 nM																		99.60%
Tanshindiol C		EZH2, IC₅₀: 0.55 μM																			98.47%
(S)-HH2853		EZH2 Y641N, IC₅₀: <100 nM
Tulmimetostat	EZH1	EZH2																			98.68%
EPZ011989 trifluoroacetate		EZH2																			98.71%
ZZM-1220							G9a, IC₅₀: 458 nM	GLP, IC₅₀: 924 nM													98.74%
PRMT5-IN-30																	PRMT5, IC₅₀: 0.33 μM PRMT5, Kd: 0.987 μM
CARM1-IN-1 hydrochloride																PRMT4
PRMT5-IN-1																	PRMT5
EML741							G9a, IC₅₀: 23 nM G9a, Kd: 1.13 μM
PRMT5-IN-4																	PRMT5				≥99.0%
(R)-HH2853		EZH2 Y641F mutant type, IC₅₀: <100 nM
NUCC-0226272		EZH2																			98.07%
Dot1L-IN-1 TFA			DOT1L																		98.56%
EPIC-0628		EZH2
CPI-1328		EZH2
BIX-01294 hydrochloride hydrate							G9a, IC₅₀: 1.7 μM	GLP, IC₅₀: 38 μM
PRMT5-IN-14																	PRMT5
GSK3368715 trihydrochloride														PRMT1, IC₅₀: 3.1 nM	PRMT3, IC₅₀: 48 nM	PRMT4, IC₅₀: 1148 nM		PRMT6, IC₅₀: 5.8 nM		PRMT8, IC₅₀: 1.7 nM
PF-06726304 acetate		EZH2 WT, Ki: 0.7 nM EZH2 Y641N, Ki: 3.0 nM
3-Deazaneplanocin A hydrochloride (GMP)		EZH2
(S)-MRTX-1719																	PRMT5
EZH2/HSP90-IN-29		EZH2, IC₅₀: 6.29 nM
DCG066							G9a
Antitumor agent-101							G9a, IC₅₀: 8.5 nM	GLP, IC₅₀: 5.5 nM
PRMT5-IN-19														PRMT1, IC₅₀: 3.252 μM		PRMT4, IC₅₀: >20 μM	PRMT5, IC₅₀: 23.9 nM
PARP/EZH2-IN-1		EZH2, IC₅₀: 36.51 nM
PRMT5-IN-23																	PRMT5
PARP/EZH2-IN-2		EZH2, IC₅₀: 27.34 ± 1. nM
CARM1-IN-4														PRMT1, IC₅₀: 56 nM	PRMT3, IC₅₀: 2637 nM		PRMT5, IC₅₀: >100,000 nM	PRMT6, IC₅₀: 30 nM		PRMT8, IC₅₀: 31 nM
PRMT5-IN-33														PRMT1, IC₅₀: 6.89 μM			PRMT5, IC₅₀: 10.9 nM
PRMT5-IN-28																	PRMT5
EZH2-IN-16		EZH2 WT, IC₅₀: 37.6 nM EZH2 Y641F mutant type, IC₅₀: 79.1 nM
UNC2327															PRMT3						99.70%
SGC2085 hydrochloride																		PRMT6, IC₅₀: 5.2 μM
LLC0424											NSD2, DC₅₀: 20 nM
MS8847		EZH2
MU1656			DOT1L, IC₅₀: 2 nM
EZH2-IN-5		EZH2 WT, IC₅₀: 1.52 nM EZH2 Y641F mutant type, IC₅₀: 4.07 nM
PRMT5-IN-9																	PRMT5, IC₅₀: 0.01 μM
EZH2-IN-4		WT 5-mer EZH2, IC₅₀: 0.923 nM mut 5-mer EZH2, IC₅₀: 2.65 nM
BBDDL2059		EZH2 Y641F mutant type, IC₅₀: 1.5 nM
PRMT5-IN-34																	PRMT5
IHMT-EZH2-426		EZH2 WT, IC₅₀: 1.3 nM EZH2-A687V, IC₅₀: 1.2 nM Y641F/Y641N/Y641S, IC₅₀: 1.7-3.5 nM
YM458		EZH2, IC₅₀: 490 nM
DM-01		EZH2																			98.03%
CSV0C018875							G9a
PRMT4-IN-1														PRMT1, IC₅₀: 0.835 μM	PRMT3, IC₅₀: 4.05 μM	PRMT4, IC₅₀: 3.2 nM	PRMT5, IC₅₀: 1.46 μM	PRMT6, IC₅₀: 1.75 μM	PRMT7, IC₅₀: 1.68 μM	PRMT8, IC₅₀: 1.95 μM
SMYD3-IN-2					SMYD3, IC₅₀: 0.81 μM μM
PRMT5-IN-21																	PRMT5
Dot1L-IN-7			DOT1L, IC₅₀: 1 μM
Dot1L-IN-1			DOT1L

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)	站点地图隐私声明
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.	沪ICP备15051369号-4

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。沪(浦)应急管危经许[2021]201709(QFYS)

站点地图隐私声明

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Histone Methyltransferase Inhibitors

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z